The PAZOREAL Non-Interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changing Metastatic Renal Cell Carcinoma Treatment Landscape.

Goebell, P., Doehn, C., Grüllich, C., Steiner, T., Ehneß, R., Welslau, M., 2016.

Ann Oncol 27(suppl_6), 852P. doi:10.1093/annonc/mdw373

Studie: PAZOREAL; Indikation: Nierenzellkarzinom; Jahr: 2016; Veranstaltung: ESMO; Journal: Annals of Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com